Adjuvant osimertinib delivers sustained long term survival benefit in EGFR mutated NSCLC

Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC

Challenges in doing clinical research in the LATAM region

Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC

Quality improvement initiative reduces chemotherapy wastage in paediatric oncology in Pakistan

Paediatric cancer treatment is a cost-effective health system investment in India

Acyclovir prophylaxis reduces varicella infections in children receiving intensive chemotherapy

Conservative management may be safe for retained central venous catheter fragments in children

Biomarker guided PARP inhibitor maintenance improves outcomes in ovarian cancer meta analysis of phase 3 trials

Immune checkpoint inhibitors show setting specific benefit in ovarian cancer meta analysis of 17 randomised trials

Prolgolimab plus chemotherapy improves long term survival in advanced nonsquamous NSCLC

Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC